FIRST TURN MANAGEMENT LLC
Q3 2024 Form 13-F

DEL MAR, DELAWARE
CIK 0001993440 · CRD 327421 · SEC-registered investment adviser
$631.6M Reported Value Total

FIRST TURN MANAGEMENT, LLC reports 3 total accounts under management (AUM). There are 3 discretionary accounts valued at $599,408,142, and 0 non-discretionary accounts.

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
SEC Registered Discretionary Manager
Private funds (Form ADV)
2 funds · $36.3M gross asset value
Hedge Fund: $36.3M
Source: Form ADV filed 2026-03-25
Reported value
$631.6M
Quarter over quarter
+10.1%
Holdings
38
Top-10 concentration
39.3%

Key People

Form ADV owners & control persons
Lisa Gable Wheatley
MANAGER
Tracy Austin Murphy
DIRECTOR
Catherine Revelle Newcomb
CHIEF COMPLIANCE OFFICER

Filing Navigation

13F Metrics

Loading 13F Metrics

Q3 2024 13F record

Q3 2024 13F filing summary

Q3 2024 Form 13F portfolio summary
Period of report September 30, 2024
Filed November 07, 2024
Form 13F-HR
Reported value $631.6M
Positions 38
Change in reported value +2.8%
New positions 13
Exited positions 11
Position turnover 49.0%
Top-10 concentration 39.3%

13F filings by quarter

Form 13F filings by quarter
Quarter Positions Value
Q3 2026 13F
Filed Nov 16, 2026
38 $753.0M
Q2 2026 13F
Filed Aug 14, 2026
31 $934.7M
Q1 2026 13F
Filed May 15, 2026
33 $895.1M
Q4 2025 13F
Filed Feb 13, 2026
33 $875.2M
Q3 2025 13F
Filed Nov 14, 2025
29 $666.0M
Q2 2025 13F
Filed Aug 14, 2025
35 $536.0M
Q1 2025 13F
Filed May 15, 2025
35 $496.1M
Q4 2024 13F
Filed Feb 14, 2025
36 $558.3M
Q3 2024 13F
Filed Nov 7, 2024
38 $631.6M
Q2 2024 13F
Filed Aug 8, 2024
36 $614.7M
Q1 2024 13F
Filed May 6, 2024
34 $668.5M
Q4 2023 13F
Filed Feb 8, 2024
31 $696.3M

Top 20 holdings · Q3 2024

Largest Q3 2024 13F positions by reported value
# Holding Reported value % of portfolio
1 NUVL NUVALENT INC $36.7M 5.82%
2 ARGX ARGENX SE $29.5M 4.67%
3 INSM INSMED INC $26.0M 4.12%
4 MIRM MIRUM PHARMACEUTICALS INC $25.3M 4.0%
5 PCVX VAXCYTE INC $24.2M 3.84%
6 AXSM AXSOME THERAPEUTICS INC $22.9M 3.63%
7 SNDX SYNDAX PHARMACEUTICALS INC $22.9M 3.62%
8 ASND ASCENDIS PHARMA A/S $22.5M 3.56%
9 NTRA NATERA INC $19.8M 3.13%
10 ITCI INTRA-CELLULAR THERAPIES INC $18.6M 2.95%
11 CRNX CRINETICS PHARMACEUTICALS IN $18.1M 2.86%
12 TMDX TRANSMEDICS GROUP INC $17.9M 2.84%
13 ACLX ARCELLX INC $17.9M 2.83%
14 BPMC BLUEPRINT MEDICINES CORP $16.6M 2.62%
15 VRNA VERONA PHARMA PLC $16.5M 2.61%
16 VRTX VERTEX PHARMACEUTICALS INC $16.4M 2.59%
17 BHVN BIOHAVEN LTD $15.8M 2.5%
18 ESTA ESTABLISHMENT LABS HLDGS INC $15.4M 2.45%
19 MRUS MERUS N V $15.4M 2.44%
20 ORIC ORIC PHARMACEUTICALS INC $14.9M 2.35%

Values as reported on the Q3 2024 Form 13F. Every position is in the holdings table below.

Filing Details

Loading Activities
Loading Sector Allocation
Crunching numbers

Performance

Loading Performance

Potential New Buys

Finding Potential New Buys

Holdings

Building table
Loading SEC filing data
Loading Form 4 Filings

Beneficial Ownership (Schedule 13D/13G)

Loading 13D/G filings